Tzu-Fei Wang: Drug–Drug Interactions Between DOACs and Prostate Cancer Therapies
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Cancer, adding:
“Concerned about drug – drug interactions between DOACs and prostate cancer therapies?
New study of 2,297 patients from Ontario and Alberta:
No increase in thrombosis with DOACs and enzalutamide or apalutamide
No increase in bleeding with DOAC and abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont , Cynthia Wu , Pietro Ravani , Dominick Bossé , Robert Talarico, Marc Carrier , Manish M. Sood
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 11, 2026, 12:58Joseph R. Shaw: Beyond Predictable Pharmacokinetics in DOAC Therapy
-
Jun 11, 2026, 12:40Khechar N Paudel: The Nepal Stroke Project Brings Evidence-Based Stroke Care to Remote Communities
-
Jun 11, 2026, 12:35Sergey Badalyan: EHA2026 Opening Ceremony – The Importance of Building Communities, Not Projects
-
Jun 11, 2026, 12:15Welcome to EHA 2026
-
Jun 11, 2026, 08:35Mohamed Reda: CBC Report – More Than Just Numbers
-
Jun 11, 2026, 07:59Uday Sankar Akash Vankayala: Key Findings on IBD-Associated VTE Phenotypes and Inpatient Burden
-
Jun 11, 2026, 07:41Zia Ullah: Hidden Cerebral Venous Sinus Thrombosis After Dengue Recovery
-
Jun 11, 2026, 07:24Aaron Rodriguez Calienes: RESISTANT Registry Provides Reassuring Safety Data for Acute Intracranial Stenting
-
Jun 11, 2026, 07:17Mbunya. S. Misiani: From the WFH Congress to Meaningful Change for Patients with Bleeding Disorders Worldwide